InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,447.87
(
-0.31%
)
US TECH 100
18,978.00
(
-1.19%
)
Dow Jones
39,411.21
(
0.67%
)
Brent Oil
85.23
(
-0.05%
)
Bitcoin
60,341.35
(
0.13%
)
Post# of 252336
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119911
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 241367

Thursday, 09/08/2022 9:53:02 AM

Thursday, September 08, 2022 9:53:02 AM

Post# of 252336
High-dose (8mg) Eylea hits primary endpoints in AMD/DME:

https://www.prnewswire.com/news-releases/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wamd-with-a-vast-majority-of-patients-maintained-on-12--and-16-week-dosing-intervals-301620404.html

Whether these results are enough to materially cut into use of the coming Eylea biosimilars remains to be seen. I'm skeptical.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up